Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C39H48FN9O4 |
| Molecular Weight | 725.8547 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN1CCN(CC1)C2CN(C2)C3=CC=CC(CN4C[C@H]5N([C@@H](CC6=CC=C(O)C=C6F)C4=O)C(=O)CN(CC=C)N5C(=O)NCC7=CC=CC=C7)=N3
InChI
InChIKey=ZGNKNLOBYFTGRG-GIWKVKTRSA-N
InChI=1S/C39H48FN9O4/c1-3-15-47-27-37(51)48-34(20-29-13-14-32(50)21-33(29)40)38(52)46(26-36(48)49(47)39(53)41-22-28-9-6-5-7-10-28)23-30-11-8-12-35(42-30)45-24-31(25-45)44-18-16-43(4-2)17-19-44/h3,5-14,21,31,34,36,50H,1,4,15-20,22-27H2,2H3,(H,41,53)/t34-,36-/m0/s1
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT03833700
Phase I study. 10, 15 and 20 mg, tablets, orally, twice daily, in 28-days treatment cycle
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
300000003820
Created by
admin on Tue Apr 01 21:20:10 GMT 2025 , Edited by admin on Tue Apr 01 21:20:10 GMT 2025
|
PRIMARY | |||
|
C153376
Created by
admin on Tue Apr 01 21:20:10 GMT 2025 , Edited by admin on Tue Apr 01 21:20:10 GMT 2025
|
PRIMARY | |||
|
91810345
Created by
admin on Tue Apr 01 21:20:10 GMT 2025 , Edited by admin on Tue Apr 01 21:20:10 GMT 2025
|
PRIMARY | |||
|
1799824-08-0
Created by
admin on Tue Apr 01 21:20:10 GMT 2025 , Edited by admin on Tue Apr 01 21:20:10 GMT 2025
|
PRIMARY | |||
|
I0DX1FG55Y
Created by
admin on Tue Apr 01 21:20:10 GMT 2025 , Edited by admin on Tue Apr 01 21:20:10 GMT 2025
|
PRIMARY |
ACTIVE MOIETY